Legal & General Group Plc increased its stake in shares of Humana Inc. (NYSE:HUM) by 4.0% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 821,442 shares of the insurance provider’s stock after buying an additional 31,842 shares during the period. Legal & General Group Plc owned approximately 0.57% of Humana worth $197,660,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in HUM. Howard Hughes Medical Institute boosted its stake in Humana by 6.2% in the first quarter. Howard Hughes Medical Institute now owns 1,178 shares of the insurance provider’s stock valued at $243,000 after buying an additional 69 shares during the period. First Citizens Bank & Trust Co. bought a new stake in Humana during the first quarter valued at approximately $3,191,000. Acadian Asset Management LLC bought a new stake in Humana during the first quarter valued at approximately $6,021,000. ProShare Advisors LLC boosted its stake in Humana by 15.8% in the first quarter. ProShare Advisors LLC now owns 17,297 shares of the insurance provider’s stock valued at $3,566,000 after buying an additional 2,356 shares during the period. Finally, Profund Advisors LLC boosted its stake in Humana by 14.6% in the first quarter. Profund Advisors LLC now owns 6,131 shares of the insurance provider’s stock valued at $1,264,000 after buying an additional 782 shares during the period. 99.13% of the stock is currently owned by institutional investors and hedge funds.
Shares of Humana Inc. (NYSE:HUM) opened at 247.28 on Friday. The firm has a market capitalization of $35.74 billion, a price-to-earnings ratio of 20.34 and a beta of 0.91. Humana Inc. has a 12-month low of $163.50 and a 12-month high of $255.27. The firm has a 50-day moving average of $241.05 and a 200 day moving average of $224.57.
Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, beating the Zacks’ consensus estimate of $3.08 by $0.41. Humana had a net margin of 3.37% and a return on equity of 15.85%. The company had revenue of $13.53 billion for the quarter, compared to analyst estimates of $13.61 billion. During the same period in the prior year, the firm posted $2.30 EPS. On average, equities research analysts expect that Humana Inc. will post $11.55 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Tuesday, August 29th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Thursday, September 28th. Humana’s dividend payout ratio is currently 13.06%.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://stocknewstimes.com/2017/08/19/humana-inc-hum-shares-bought-by-legal-general-group-plc.html.
Several research firms have recently commented on HUM. UBS AG reissued a “neutral” rating and set a $250.00 price target (up from $237.00) on shares of Humana in a research note on Wednesday, August 9th. BidaskClub raised shares of Humana from a “sell” rating to a “hold” rating in a research note on Thursday, August 10th. Cantor Fitzgerald reissued a “neutral” rating and set a $223.00 price target (up from $200.00) on shares of Humana in a research note on Thursday, August 3rd. Morgan Stanley increased their price target on shares of Humana from $269.00 to $276.00 and gave the company an “overweight” rating in a research note on Thursday. Finally, Jefferies Group LLC reissued a “hold” rating and set a $257.00 price target on shares of Humana in a research note on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. Humana presently has an average rating of “Hold” and an average price target of $244.35.
In other news, VP M Todoroff Christopher sold 22,935 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $252.52, for a total value of $5,791,546.20. Following the sale, the vice president now directly owns 24,001 shares of the company’s stock, valued at approximately $6,060,732.52. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Bruce D. Broussard sold 12,000 shares of the company’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $251.88, for a total transaction of $3,022,560.00. Following the completion of the sale, the chief executive officer now directly owns 80,086 shares in the company, valued at $20,172,061.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 41,406 shares of company stock worth $10,355,086. Insiders own 0.80% of the company’s stock.
About Humana
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
